• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

An optimum prophylactic dose of prasugrel monotherapy may safely and effectively prevent the development of experimental thrombotic strokes
Myocardial infarction and stroke are two of the leading causes of death and disability worldwide [1,2]. Using a combination of aspirin and a platelet P2Y12 antagonist, several large clinical trials have definitively demonstrated the efficacy of dual antiplatelet therapies in preventing myocardial infarction, stroke or death in patients with acute coronary syndromes [3–8]. Dual antiplatelet therapy with aspirin and a thienopyridine-based P2Y12 antagonist (clopidogrel or prasugrel) has now become the standard of care of patients with acute coronary syndromes.
Source: Thrombosis Research - October 16, 2015 Category: Hematology Authors: Frederick A. Ofosu Source Type: research

Soluble P-selectin: The next step
It has long been recognised that platelets are implicated in both mortality and morbidity in the pathophysiology of a variety of conditions, including coronary artery disease , diabetes , cancer , stroke , and deep vein thrombosis . The success of aspirin in reducing thrombotic events, and the prognostic value of platelet volume, numbers and function in predicting cardiovascular death are further evidence of the importance of this cell. Consequently, the ability to accurately identify those subjects at risk of thrombosis, and possibly those experiencing an acute thrombotic event, is highly sought-after if risk reduction an...
Source: Thrombosis Research - November 11, 2013 Category: Hematology Authors: Andrew D. Blann Tags: Editorials Source Type: research

Cost-effectiveness of Apixaban versus Warfarin and Aspirin in Sweden for Stroke Prevention in Patients with Atrial Fibrillation
Source: Thrombosis Research - May 26, 2014 Category: Hematology Authors: Tereza Lanitis, Thitima Kongnakorn, Lena Jacobson, Anna De Geer Source Type: research

Normal Platelet Activation Profile in Patients with Peripheral Arterial Disease on Aspirin
Peripheral arterial disease (PAD) is a progressive vascular disease associated with a high risk of cardiovascular morbidity and death. Antithrombotic prevention is usually applied by prescribing the antiplatelet agent aspirin. However, in patients with PAD aspirin fails to provide protection against myocardial infarction and death, only reducing the risk of ischemic stroke. Platelets may play a role in disease development, but this has not been tested by proper mechanistic studies. In the present study, we performed a systematic evaluation of platelet reactivity in whole blood from patients with PAD using two high-throughput assays, i.e.
Source: Thrombosis Research - January 5, 2015 Category: Hematology Authors: Johanna P. van Geffen, Marie-Claire Kleinegris, Remco Verdoold, Constance C.F.M.J. Baaten, Judith M.E.M. Cosemans, Kenneth J. Clemetson, Hugo ten Cate, Mark Roest, Bas de Laat, Johan W.M. Heemskerk Tags: Regular article Source Type: research

The use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disorders
Cardiovascular disease (CVD) includes a number of conditions such as myocardial infarction, coronary heart disease, stroke, and venous thromboembolism. CVD is a leading health problem worldwide and a major cause of mortality, morbidity, and disability; it is also associated with high healthcare costs. The incidence of CVD is predicted to increase in the forthcoming years, and thus it is crucial that physicians are aware of the benefits and limitations of the available therapies to ensure patients receive optimized treatment.
Source: Thrombosis Research - December 12, 2014 Category: Hematology Authors: A.T. Cohen, S. Imfeld, J. Markham, S. Granziera Tags: Review Article Source Type: research

Is platelet transfusion the solution to reverse platelet inhibition in patients on triple antiplatelet therapy?
Antiplatelet therapy is the cornerstone of secondary prevention against acute thrombotic events in patients with cardiovascular disease [1]. Health Organizations around the world recommend combination therapy with aspirin and a P2Y12 receptor inhibitor for up to one year following an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI), and lifelong aspirin therapy thereafter [2]. Vorapaxar, a first-in-class novel protease-activated receptor (PAR)-1 antagonist, was approved in addition to standard antiplatelet therapy, to further reduce the risk of myocardial infarction (MI), stroke, cardiovascular dea...
Source: Thrombosis Research - October 30, 2015 Category: Hematology Authors: Marie Lordkipanidzé Source Type: research

Arguments favoring low versus high dose aspirin in the prophylaxis of venous thromboembolism
The use of aspirin in the prevention of venous thromboembolism (VTE) is still controversial. In a profound review on the use of aspirin for primary and secondary prevention of venous thromboembolism and other cardiovascular disorders Cohen et al. [1] conclude that the benefits of aspirin are well documented for conditions like myocardial infarction, coronary heart disease, and stroke, but less clearly for prevention of VTE after orthopedic surgery. The latter indistinctness has been a matter of concern in many earlier reviews and meta-analyses, and has even led to non-uniform guidelines on VTE prevention from the American ...
Source: Thrombosis Research - January 27, 2016 Category: Hematology Authors: Piet Borgdorff, Geert Jan Tangelder Tags: Correspondence Source Type: research

Platelet reactivity in patients carrying the e-NOS G894T polymorphism after a loading dose of aspirin plus clopidogrel
Nitric oxide (NO) plays an important role in the modulation of platelet reactivity through platelet recruitment, activation and aggregation. NO is produced by the endothelial NO synthase (eNOS) that is expressed not only in the endothelium but also in platelets [1]. G894T single nucleotide polymorphism of eNOS gene results in the substitution of glutamic acid at codon 298 by aspartic acid. This substitution in the protein sequence is responsible of lower enzyme activity, i.e. lower NO production, and it has been associated with coronary spasm, atherosclerosis, myocardial infarction, and stroke [2 –6].
Source: Thrombosis Research - January 25, 2017 Category: Hematology Authors: Teresa Strisciuglio, Giuseppe Di Gioia, Fabio Mangiacapra, Chiara De Biase, Leen Delrue, Mariano Pellicano, Jozef Bartunek, Marc Vanderheyden, Raffaele Izzo, Bruno Trimarco, William Wijns, Emanuele Barbato Tags: Letter to the Editors-in-Chief Source Type: research

Serum thromboxane B2 but not soluble P-selectin levels identify ischemic stroke patients with persistent platelet reactivity while on aspirin therapy
Aspirin non-response due to persistent platelet reactivity has been associated with adverse vascular events. Light transmission aggregometry (LTA), the ‘gold standard’ for measuring the platelet response to aspirin therapy, is a cumbersome procedure and a simple and reliable alternative is required. Our aim was to explore whether serum thromboxane B2 (sTXB2) and soluble P-selectin can be used to identify patients who are at risk of increased pl atelet reactivity while on aspirin.
Source: Thrombosis Research - October 28, 2021 Category: Hematology Authors: Pandarisamy Sundaravadivel, Rita Christopher, Nitin C. Ramanujam, Sadanandavalli Retnaswami Chandra Tags: Full Length Article Source Type: research